Paper Details

  1. Home
  2. Paper Details

Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.

Author: HeidenreichA, HofmannR, von KnoblochR

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Hormone-refractory prostate cancer (HRPCA) is a challenging condition to treat. Combinations of estramustine phosphate with taxanes and etoposide are the most effective cytotoxic therapies. Mitoxantrone also shows palliative effects. Future research should focus on identifying prognostic factors and developing targeted therapies.
Paper Details　
Original Abstract of the Article :
Adenocarcinoma of the prostate is the most prevalent neoplastic disease in men and continues to be a major cause of morbidity and mortality. Death from prostate cancer is associated with objective and biochemical progression following hormonal manipulations often described as hormone refractory pros...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000052426

データ提供：米国国立医学図書館（NLM）

Cytotoxic Chemotherapy for Hormone Refractory Prostate Cancer: A Complex Treatment Landscape

Prostate cancer is a common and potentially life-threatening disease. This research focuses on the treatment of hormone refractory prostate cancer (HRPCA), a challenging stage of the disease where the cancer has become resistant to hormonal therapies. The authors examine the current status of cytotoxic chemotherapy in the management of HRPCA and discuss the complexities of treatment decisions.

Navigating Treatment Options for HRPCA

The study highlights the limited therapeutic options for HRPCA and emphasizes the need to balance potential benefits with the associated side effects. The authors discuss various cytotoxic chemotherapy regimens, including combinations of estramustine phosphate with taxanes and etoposide, and explore the potential of other therapies such as mitoxantrone and oral chemotherapeutic regimens.

The Need for Further Research and Personalized Treatment Plans

This research underscores the ongoing need for further research and clinical trials to improve the treatment of HRPCA. The authors emphasize the importance of individualized treatment plans, considering patient factors and prognostic indicators to optimize treatment outcomes.

Dr. Camel's Conclusion

Just as a camel navigates a challenging desert landscape, treating HRPCA requires a carefully considered and individualized approach. This research highlights the complexities of this disease and the ongoing need for innovative treatment strategies.

Date :
  1. Date Completed 2001-06-14
  2. Date Revised 2018-02-13
Further Info :

Pubmed ID

11223670

DOI: Digital Object Identifier

10.1159/000052426

Related Literature

Article Analysis
・Side Effects of estramustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.